Özet:

Introduction and Purpose: Fraktalkine is a chemotactic agent that shows both tumorogenic and anti-tumorogenic activity in some types of cancer. In this study, we studied the role of fraktalkinine in the diagnosis, nursing and progression of primary non-muscle invasive cervical cancer. Method and Requirements: The study included a total of 84 people, including 44 patients diagnosed with primary non-invasive muscle cervical cancer and 40 people with a healthy control group. Blood and urine samples were collected and the level of fraktalkin was assessed by the ELISA method. The levels of urine creatine were calculated and the level of urine fractalkine was optimized. Demographic data, the tumor stage (Ta, T1), the degree (low, high), the number, size and recurrence, the progression state was recorded. Fraktalkine levels and subgroup analyses were compared between both groups. The patient group was tested NMP22 and urinary cytology was sent from the patient. The patient’s average age was 63.9±11.1 and 62.3±9.6 in the control group. The average level of urine fractaline was 7.8±0.9 ng/ml in patients and 7.7±0.6 ng/ml in the control group, and there was no statistically significant difference between the two groups (p=0.426). The average urine fractalkin/creatin value was similar between two groups (respectively, 16.0±32.2 ng/mgCr and 11.1±7.0 ng/mgCr, p=0.781). The average serum fractalkine level was 2.9±1.2 ng/ml in the patient group and 2.9±0.7 ng/ml in the healthy control group, and there was no statistically significant difference between the two groups (p=0.183). At the same time, there was no connection between the level of fractalkine and the tumor size, number, nuts and progressive condition. The level of fractalkine in the NMP22 test was statistically significantly higher in positive patients than in negative patients. The cytology was positive in 45.5 percent of patients, but there was no statistically meaningful relationship with the fractalkine values. This study found similar levels of serum and urine fractalkin between both groups, and found that fractalkin could not be used as a biomarker in primary mesh cancer patients.

Anahtar Kelimeler: